Meeting
2021 ASCO Annual Meeting
Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).
Authors
Ana Christina Garrido-Castro
Dana-Farber Cancer Institute, Boston, MA
Ana Christina Garrido-Castro , Tanya Elizabeth Keenan , Tianyu Li , Paulina Lange , Catherine Callahan , Jennifer Guerriero , Nabihah Tayob , Leilani Anderson , Clinton Yam , Brooke R. Daniel , Lisa A. Carey , Rita Nanda , Eric P. Winer , Elizabeth A. Mittendorf , Sara M. Tolaney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT04468061
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS1106)
DOI
10.1200/JCO.2021.39.15_suppl.TPS1106
Abstract #
TPS1106
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).
First Author: Ana Christina Garrido-Castro
Poster
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
First Author: Natalie Rainey
Poster
2022 ASCO Annual Meeting
Association of 27-gene IO score with outcome in a phase Ib trial of pembrolizumab (pembro) plus chemotherapy (CT) in metastatic triple-negative breast cancer (mTNBC).
First Author: David B. Page
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi